- Home
- PBYI vs EVG Comparison
PBYI vs EVG Comparison
Compare PBYI & EVG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBYI
- EVG
- Stock Information
- Founded
- PBYI 2010
- EVG 2005
- Country
- PBYI United States
- EVG United States
- Employees
- PBYI N/A
- EVG N/A
- Industry
- PBYI Biotechnology: Pharmaceutical Preparations
- EVG Investment Managers
- Sector
- PBYI Health Care
- EVG Finance
- Exchange
- PBYI Nasdaq
- EVG Nasdaq
- Market Cap
- PBYI 154.1M
- EVG 149.9M
- IPO Year
- PBYI N/A
- EVG N/A
- Fundamental
- Price
- PBYI $3.14
- EVG $10.98
- Analyst Decision
- PBYI Strong Buy
- EVG
- Analyst Count
- PBYI 1
- EVG 0
- Target Price
- PBYI $7.00
- EVG N/A
- AVG Volume (30 Days)
- PBYI 418.2K
- EVG 49.4K
- Earning Date
- PBYI 05-01-2025
- EVG 01-01-0001
- Dividend Yield
- PBYI N/A
- EVG 8.68%
- EPS Growth
- PBYI 37.78
- EVG N/A
- EPS
- PBYI 0.62
- EVG N/A
- Revenue
- PBYI $230,468,000.00
- EVG N/A
- Revenue This Year
- PBYI N/A
- EVG N/A
- Revenue Next Year
- PBYI $3.27
- EVG N/A
- P/E Ratio
- PBYI $5.06
- EVG N/A
- Revenue Growth
- PBYI N/A
- EVG N/A
- 52 Week Low
- PBYI $2.23
- EVG $9.13
- 52 Week High
- PBYI $6.06
- EVG $10.86
- Technical
- Relative Strength Index (RSI)
- PBYI 45.33
- EVG 46.70
- Support Level
- PBYI $3.14
- EVG $10.91
- Resistance Level
- PBYI $3.56
- EVG $11.24
- Average True Range (ATR)
- PBYI 0.19
- EVG 0.12
- MACD
- PBYI -0.05
- EVG 0.01
- Stochastic Oscillator
- PBYI 17.54
- EVG 43.48
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.